Founding Donor Partners with Imperial College London to Develop COVID-19 Vaccine
Morningside Ventures has partnered with Imperial College London to develop a vaccine against COVID-19 using the novel technology of self-amplifying RNA. This endeavor, reported in The New York Times, is structured as a social enterprise called VacEquity Global Health and aims to make the vaccine affordable in low-income regions of the world. The Morningside Group, of which Morningside Ventures is the venture capital arm, was founded by the Chan family of Hong Kong in 1986, and in addition to providing the founding donation for Morningside College, has also generously funded the T.H. Chan School of Public Health at Harvard University.